AzTrials
AzTrials

Pain ControlVCAMNCT06986122

Virtual Contexts for Affective Modulation

A study testing Pain Threat Manipulation in people with Pain Control and Anxiety, run by Trustees of Dartmouth College at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This study investigates how spatial context and perceived controllability modulate pain, affective states such as anxiety, and motivated behavior. The study examines how control over pain and threat-related environments influences pain perception, state anxiety, associated autonomic responses, and behavior. Read more about this study

Who is it for?
Ages 18 to 55 yearsHealthy volunteers can take part
Conditions the study is for
Pain Control, Anxiety, Memory
What is being tested?
Pain Threat Manipulation
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
1 siteUnited States
Study dates
28 Oct 2025to 15 Jun 2029
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 55 years
  • All sexes
  • Healthy volunteers accepted
  • Adult
  • No self-reported current or history of depression, bipolar disorder, or other psychiatric diagnosis
  • No self-reported current seizure disorder (i.e., seizure within past 10 years), or history of stroke or other major neurological diagnosis
  • No self-reported current chronic pain, or acute pain within three months of the study period
  • No current migraine disorder (i.e., 15 headache days or more in 1 month)
  • No use of central nervous system-effective medication or other medication for neurological/psychiatric treatment
  • No self-reported substance abuse within the last six months
  • No contraindication to MRI (e.g., pregnancy, claustrophobia, pacemakers, ear/cochlear implants, shrapnel injuries, clips, or other ferromagnetic/electrical objects/devices, diagnosed brain abnormality such as tumor, or skin lesions on the scalp.)
  • No contraindications for induced pain (e.g., no heart disease, high blood pressure, heart surgery, heart problems of any kind, severe asthma, respiratory problems of any kind, fibromyalgia, Raynaud's Syndrome or Disease, chronic pain, diabetes)
  • Participants must be capable of performing experimental tasks (e.g., are able to read), are fluent or native speakers of English
  • Participants must be able to tolerate the maximum level of thermal pain stimuli (for thermal stimuli)

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Tor D Wager, PhD contact

3038958739

tor.d.wager@dartmouth.edu

Vivek Sagar, PhD contact

vivek.sagar@dartmouth.edu

United States1 site, 1 recruiting
  • Dartmouth College

    Hanover, New Hampshire, 03755

    Sydney Shohan

    Recruiting

Other trials in United States

About this study

Official title: Controllability of Virtual Contexts for the Modulation of the Affective Experience

This study investigates how spatial context and perceived controllability modulate pain, affective states such as anxiety, and motivated behavior. The study examines how control over pain and threat-related environments influences pain perception, state anxiety, associated autonomic responses, and behavior. The main questions it aims to answer are:

Does having control over pain within specific contexts alter how much pain people feel-even when the stimulus intensity remains constant? How do different types of environments (safe, controllable, or uncontrollable) shape pain-related brain activity, subjective anxiety, and physiological arousal? How do people perform cognitively demanding or distracting tasks (and retain their memory) when under threat versus when in control? Lastly, how do these learned associations with spatial contexts persist or adapt when environmental contingencies are explicitly changed?

Taken together, exploration of these factors may lay the groundwork for understanding how placebo-related mechanisms-including perceived control, contextual learning, emotional engagement, and distraction-interact to shape pain and anxiety in complex environments.

Read the detailed description

The study investigates how perceived controllability and threat-related spatial contexts influence pain perception, affective state, autonomic responses, and behavior. Specifically, it aims to dissect the systems-level mechanisms by which humans interpret and respond to painful experiences in environments that differ in perceived threat and agency. These mechanisms-spanning from pain perception to context-driven learning and flexible adaptation-are central to understanding both everyday coping and the cognitive underpinnings of placebo effects.

Participants will explore three distinct virtual rooms, each associated with a different contingency: one room is safe (no pain), one involves controllable threat (participants can use a button to temporarily suppress incoming thermal pain), and one involves uncontrollable threat (pain occurs and cannot be avoided). The context-pain contingencies are learned across repeated exposures. While in each room, participants will also engage in a distracting maze-navigation task requiring them to press a sequence of levers to escape. This setup allows measuring immediate control over pain (via the button) and motivated behavior under threat (via navigation performance).

Following primary outcomes are measured:

  1. Subjective pain reports following each stimulus,
  2. Anxiety responses (based on self-reports and inferred from autonomic responses e.g., skin conductance, breathing, heart rate).

In addition, navigation behavior and brain activity via functional MRI is also monitored (as subjects perform various tasks inside the scanner).

In a later phase, extinction or reversal learning will occur: all rooms will deliver identical, uncontrollable pain, or participants will be instructed that previous contingencies have changed. Here the investigators probe how learned threat and control associations persist, generalize, or adapt, and how placebo-relevant mechanisms like expectation, context, and cognitive reappraisal interact to shape pain and behavior. By independently manipulating context, control, and task goals, this design captures a rich profile of how humans flexibly regulate threat and pain in complex environments. This is a key step in examining the key factors that may contribute to the placebo effect under a joint paradigm: namely, the agency/controllability, place context and engagement/distraction.

The following aims are examined in this study:

Aim 1: How spatial contexts associated with safety, controllable threat, or uncontrollable threat influence subjective pain perception and behavioral responses. The first hypothesis is that controllability of pain (Context B vs C) could produce analgesia. This controllability associated with context is likely to persist during extinction.

Aim 2: The investigators aim to characterize the neural circuits supporting contextual threat learning, controllability, and pain modulation. The second hypothesis is that the hippocampus will differentiate spatial contexts, Amygdala will show heightened activity in the uncontrollable threat context, and analgesia may incorporate activity in periaqueductal gray (PAG) and opioid-related midbrain circuits.

Aim 3: The third aim is to examine the effect of threat and behavioral control on the autonomic markers such as breathing, skin-conductance and heart rate. The corresponding hypothesis is that a multidimensional marker of threat-state and anxiety could be derived from these features that may be sensitive to various contexts and controllability.

Aim 4: Next aim is to study how the affective state induced by different threat contexts (safe, controllable, uncontrollable) modulates incidental visual memory for the contexts.

Aim 5: The final is aim to study how the context-outcome associations are generalized to new contexts and dynamically updated when subjects are explicitly instructed to do so. The corresponding hypothesis is that this generalization or reversal might be dependent upon hippocampus-OFC interactions.

The study design consists of the following sessions:

  1. Session 1: Consent, Familiarization, and Baseline Assessment (~1.5 hours): As part of the screening process, a pain calibration procedure is performed on each participant in order to ensure that all temperatures delivered during any subsequent procedures are within participants' tolerable range. The pain calibration procedure consists of applying a range of temperatures to various sites on the subject's skin. Participants rate each stimulus using the provided scale and respond to two prompts ("Painful?" and "Tolerable?"). The ratings are used to fit a mathematical relationship between noxious stimulus and reported pain. Subjects will not be permitted to continue participation if their pain tolerances are too high (hypersensitive) or too low (hyposensitive) -i.e., those that would require delivery of temperatures above the boundaries stipulated by the guidelines in this protocol, or that do not allow for sufficient experimental variation of the temperatures delivered. Further, subjects will be familiarized with virtual contexts without any pain. Participants will explore 3 visually distinct virtual "rooms" (contexts A, B, C) via a non-immersive VR setup (e.g., monitor-based navigation). Participants learn to recognize rooms but are not told of any contingencies. Participants navigate through the rooms in a block of 15 trials (5 trials per context, 1 trial ≈ 1-1.5 min) and learn to solve an escape task (by activating a set of levers in a sequence). Subjects are later tested on a spatial context identification task to confirm room encoding (with participants performing below chance removed from the study).
  2. Session 2: Threat Learning and Controllability Manipulation (~1 hour): The experimental session will be conducted in the MRI. Following a consenting process, participants will be acquainted with MRI safety guidelines. Once in the scanner, subjects will perform the task in 4 blocks of 15 trials each (60 trials, 1 trial = 1-2 minutes, 20 trials per context). In each room, subjects learn to perform a navigational task (such as activating a sequence of switches) to proceed to the next room. Each virtual room is paired with consistent contingency. Room A: Safe - no pain is delivered. Room B: Controllable threat - pain is delivered but can be avoided by pressing a button that the subjects have access to. Room C: Uncontrollable threat - pain is delivered and cannot be avoided (statistically similar amount of pain is administered as Room B). In each trial, participants rate pain, perceived control, and room aversiveness. Subjects' autonomic responses and behavioral responses (e.g. instantaneous position, velocity etc.) are recorded throughout the sessions. A T1 anatomical image of the subject's brain will also be acquired to localize the ROIs. Following the training, subjects perform a visual memory task where they are shown images from the three contexts as well as novel ones and asked to report if they recall seeing them.
  3. Session 3: Extinction (~1.5-2 hours) In the subsequent session, all three rooms are now presented with uncontrollable pain, regardless of prior association. Participants are not informed of the change; the goal is to assess spontaneous extinction and memory persistence. The session has the same trial timing and structure as Session 2.
  4. Session 4-5: Reversal and generalization blocks (~1.5-2 hours) For a subset of subjects, after initial extinction, the threat conditions are reinstated. Following the reinstatement, the contingencies are reversed (e.g., Room B now becomes unsafe). Participants are explicitly instructed about the reversal (instructed learning). The remaining trial structure is similar to session-2. Subjects are also presented with novel contexts that may be similar or dissimilar to the original contexts.

Before each session, participants are advised to get 8 hours of sleep, and not to consume any alcohol or central acting drugs or pain medication for at least 24 h before each experiment.

Below are the set of detailed hypotheses for the study:

  1. Pain Report: Pain is lower in controllable context (B) than uncontrollable (C) in Session 2; in Session 3, pain reports will reflect memory of control: B < C > A, even though all contexts are now uncontrollable.
  2. Autonomic Arousal: Skin conductance and breathing rate can distinguish C vs. A (threat vs. safety); threat signals will be lower in B than C during Session 2, and in Session 3, threat memory will persist: C > B > A. Similarly, self-reported anxiety will be higher in the uncontrollable context (C) than in B or A, and may correlate with autonomic arousal.
  3. Pain Report + Autonomic: Individuals showing stronger autonomic arousal in C will also report higher pain, even with identical stimulation.
  4. Navigational Efficiency: Task performance may differ between B and C due to the cognitive load of controlling pain under threat.
  5. Incidental Visual Memory: Memory for visual details may be enhanced in high-arousal contexts (C).

Together, this multi-session design provides a comprehensive framework to investigate how controllability, spatial context, and cognitive engagement interact to shape pain, anxiety, and adaptive behavior. The findings from the study form a foundation for understanding placebo-like modulation of pain and affect in complex, real-world environments.

Being tested
Pain Threat Manipulation, Pain Controllability Manipulation
Keywords
Place conditioning, controllability of pain
Medical subject headings
Agnosia, Anxiety Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Pain Threat ManipulationBehavioural

    Participants receive brief thermal pain stimuli in certain virtual environments to examine how threat influences perception and physiological responses.

  • Pain Controllability ManipulationBehavioural

    In some contexts, participants can reduce or avoid pain using a button; in others, no action changes the outcome. This manipulation is used to study the effects of perceived control over pain.

Study groups in NCT06986122
Study groupRoleWhat they receive
Contextual learningExperimentalAll participants complete trials in three virtual contexts (safe, controllable threat, uncontrollable threat), with pain controllability and task performance assessed across all conditions in a randomized within-subject design.
Receives: Behavioral: Pain Threat Manipulation; Behavioral: Pain Controllability Manipulation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Pain Intensity Ratings

    Self-reported pain level following each thermal stimulus, measured on a visual analog scale. 0-100 scale with 0 indicating no pain and higher values indicating more pain.

    Measured: 3-10 sec post-stimulus throughout testing sessions, on average complete within 1 month

  2. Self-Reported Anxiety Ratings

    Participants rate their current level of anxiety using a 0-100 visual analogue Subjective Units of Distress Scale (SUDS). 0 indicates no anxiety and higher values indicating more anxiety.

    Measured: Every 45-60 sec throughout testing sessions, on average complete within 1 month

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 May 2025
  2. Study start28 Oct 2025
  3. Primary completion15 Jun 2027 (estimated)
  4. Study completion15 Jun 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
20 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06986122
Sponsor's protocol ID
STUDY00033386
Acronym
VCAM
Status last verified
Oct 2025
First submitted
8 May 2025
Last updated
31 Oct 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: IPD may be shared to assist with any supplementary or meta-analyses after de-identification of subjects.

Publications

  • Tzschentke TM. Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. Prog Neurobiol. 1998 Dec;56(6):613-72. doi: 10.1016/s0301-0082(98)00060-4.

    PubMed 9871940
  • Salomons TV, Nusslock R, Detloff A, Johnstone T, Davidson RJ. Neural emotion regulation circuitry underlying anxiolytic effects of perceived control over pain. J Cogn Neurosci. 2015 Feb;27(2):222-33. doi: 10.1162/jocn_a_00702.

    PubMed 25208742
  • Salomons TV, Johnstone T, Backonja MM, Davidson RJ. Perceived controllability modulates the neural response to pain. J Neurosci. 2004 Aug 11;24(32):7199-203. doi: 10.1523/JNEUROSCI.1315-04.2004.

    PubMed 15306654
  • Kragel PA, Kano M, Van Oudenhove L, Ly HG, Dupont P, Rubio A, Delon-Martin C, Bonaz BL, Manuck SB, Gianaros PJ, Ceko M, Reynolds Losin EA, Woo CW, Nichols TE, Wager TD. Generalizable representations of pain, cognitive control, and negative emotion in medial frontal cortex. Nat Neurosci. 2018 Feb;21(2):283-289. doi: 10.1038/s41593-017-0051-7. Epub 2018 Jan 1.

    PubMed 29292378
  • Atlas LY, Bolger N, Lindquist MA, Wager TD. Brain mediators of predictive cue effects on perceived pain. J Neurosci. 2010 Sep 29;30(39):12964-77. doi: 10.1523/JNEUROSCI.0057-10.2010.

    PubMed 20881115
  • Amat J, Baratta MV, Paul E, Bland ST, Watkins LR, Maier SF. Medial prefrontal cortex determines how stressor controllability affects behavior and dorsal raphe nucleus. Nat Neurosci. 2005 Mar;8(3):365-71. doi: 10.1038/nn1399. Epub 2005 Feb 6.

    PubMed 15696163
  • Alvarez RP, Biggs A, Chen G, Pine DS, Grillon C. Contextual fear conditioning in humans: cortical-hippocampal and amygdala contributions. J Neurosci. 2008 Jun 11;28(24):6211-9. doi: 10.1523/JNEUROSCI.1246-08.2008.

    PubMed 18550763

Questions about this trial

What is this clinical trial studying?

A study testing Pain Threat Manipulation in people with Pain Control and Anxiety, run by Trustees of Dartmouth College at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 31 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Tor D Wager, PhD (3038958739, tor.d.wager@dartmouth.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Pain Intensity Ratings (time frame: 3-10 sec post-stimulus throughout testing sessions, on average complete within 1 month). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06986122, which also lists 7 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Oct 2025.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in